Abstract: This invention relates to novel substituted 1,4-benzodioxine compounds having antidiabetic, andihyperglycemic, and antiobesity properties represented by the formula ##STR1## wherein R.sup.1 and R.sup.6 are independently hydrogen, C.sub.1 to C.sub.6 alkyl, trifluoromethyl, cyano, C.sub.1 to C.sub.6 alkoxy, or halogen;R.sup.2 is hydrogen or C.sub.1 to C.sub.6 trialkylsilyl; R.sup.3 is hydrogen or C.sub.1 to C.sub.6 alkoxycarbonyl;or R.sup.2 and R.sup.3 are joined to form the oxazolidinone ring ##STR2## R.sup.4 and R.sup.5 are independently hydrogen or C.sub.1 to C.sub.6 alkyl; R.sup.7 and R.sup.8 are independently hydrogen OR.sup.9 or NR.sup.10 R.sup.11 ;R.sup.9 is hydrogen, C.sub.1 to C.sub.12 alkyl, C.sub.1 to C.sub.12 cycloalkyl, C.sub.1 to C.sub.12 silylalkyl, phenyl, naphthyl, phenyl C.sub.1 to C.sub.6 alkyl, C.sub.1 to C.sub.6 alkoxy C.sub.1 to C.sub.6 alkyl, pyridyl, thiophenyl, furanyl, imidazolyl, oxazolyl, --CHR.sup.12 COOR.sup.13, --CHR.sup.12 C(O)R.sup.13, --CHR.sup.12 CONR.sup.10 R.sup.11, --CHR.